The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies strongly reliant on generic versions presents a complex picture. While early earnings were significant, the expiration of patents and the rise of cheaper alternatives have diminished market share. Consequently, a thorough analysis of